apnews.com · 4 min
A cancer treatment using mRNA succeeded in a late-state trial | AP NewsModerna and Merck's personalized mRNA vaccine lowered the two-year melanoma return rate by 42% in a late-stage trial. This is the strongest signal yet that mRNA vaccines can work beyond COVID, though the custom-built approach will be expensive to scale.




